Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab with or without FESS for chronic rhinosinusitis with nasal polyps
2022-002923-37Phase 4Active
- Sponsor
- Rigshospitalet
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in SNOT-22 at 6 months. Started Nov 2022; status: active.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2022-002923-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002923-37.